BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1141 related articles for article (PubMed ID: 27158780)

  • 21. Combined double CK5/P63 stain: useful adjunct test for diagnosing pulmonary squamous cell carcinoma.
    Fatima N; Cohen C; Lawson D; Siddiqui MT
    Diagn Cytopathol; 2012 Nov; 40(11):943-8. PubMed ID: 21472873
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Integrative genomic analyses identify BRF2 as a novel lineage-specific oncogene in lung squamous cell carcinoma.
    Lockwood WW; Chari R; Coe BP; Thu KL; Garnis C; Malloff CA; Campbell J; Williams AC; Hwang D; Zhu CQ; Buys TP; Yee J; English JC; Macaulay C; Tsao MS; Gazdar AF; Minna JD; Lam S; Lam WL
    PLoS Med; 2010 Jul; 7(7):e1000315. PubMed ID: 20668658
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Personalized therapy on the horizon for squamous cell carcinoma of the lung.
    Kim HS; Mitsudomi T; Soo RA; Cho BC
    Lung Cancer; 2013 Jun; 80(3):249-55. PubMed ID: 23489560
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The distinct metabolic phenotype of lung squamous cell carcinoma defines selective vulnerability to glycolytic inhibition.
    Goodwin J; Neugent ML; Lee SY; Choe JH; Choi H; Jenkins DMR; Ruthenborg RJ; Robinson MW; Jeong JY; Wake M; Abe H; Takeda N; Endo H; Inoue M; Xuan Z; Yoo H; Chen M; Ahn JM; Minna JD; Helke KL; Singh PK; Shackelford DB; Kim JW
    Nat Commun; 2017 May; 8():15503. PubMed ID: 28548087
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comprehensive analysis of oncogenic mutations in lung squamous cell carcinoma with minor glandular component.
    Pan Y; Wang R; Ye T; Li C; Hu H; Yu Y; Zhang Y; Wang L; Luo X; Li H; Li Y; Shen L; Sun Y; Chen H
    Chest; 2014 Mar; 145(3):473-479. PubMed ID: 24158231
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Detection of PIK3CA mutations, including a novel mutation of V344G in exon 4, in metastatic lung adenocarcinomas: A retrospective study of 115 FNA cases.
    Allison DB; Lilo MT; Geddes S; Pallavajjalla A; Askin F; Gabrielson E; Zheng G; Li QK
    Cancer Cytopathol; 2016 Jul; 124(7):485-92. PubMed ID: 27007084
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pleomorphic (giant and spindle cell) carcinoma is genetically distinct from adenocarcinoma and squamous cell carcinoma by K-ras-2 and p53 analysis.
    Przygodzki RM; Koss MN; Moran CA; Langer JC; Swalsky PA; Fishback N; Bakker A; Finkelstein SD
    Am J Clin Pathol; 1996 Oct; 106(4):487-92. PubMed ID: 8853037
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MicroRNA profiling in lung cancer reveals new molecular markers for diagnosis.
    Solomides CC; Evans BJ; Navenot JM; Vadigepalli R; Peiper SC; Wang ZX
    Acta Cytol; 2012; 56(6):645-54. PubMed ID: 23207443
    [TBL] [Abstract][Full Text] [Related]  

  • 29. p40 (ΔNp63) is more specific than p63 and cytokeratin 5 in identifying squamous cell carcinoma of bronchopulmonary origin: a review and comparative analysis.
    Vogt AP; Cohen C; Siddiqui MT
    Diagn Cytopathol; 2014 May; 42(5):453-8. PubMed ID: 24166777
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mutations of K-ras oncogene and absence of H-ras mutations in squamous cell carcinomas of the lung.
    Vachtenheim J; Horáková I; Novotná H; Opáalka P; Roubková H
    Clin Cancer Res; 1995 Mar; 1(3):359-65. PubMed ID: 9815992
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of cell-type specific profiles in tissues and isolated cells from squamous cell carcinomas of the lung.
    Hawthorn L; Stein L; Panzarella J; Loewen GM; Baumann H
    Lung Cancer; 2006 Aug; 53(2):129-42. PubMed ID: 16757060
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Arsenic-related DNA copy-number alterations in lung squamous cell carcinomas.
    Martinez VD; Buys TP; Adonis M; Benítez H; Gallegos I; Lam S; Lam WL; Gil L
    Br J Cancer; 2010 Oct; 103(8):1277-83. PubMed ID: 20842114
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pulmonary large cell carcinoma lacking squamous differentiation is clinicopathologically indistinguishable from solid-subtype adenocarcinoma.
    Hwang DH; Szeto DP; Perry AS; Bruce JL; Sholl LM
    Arch Pathol Lab Med; 2014 May; 138(5):626-35. PubMed ID: 23738762
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of tumor TROP2 expression with prognosis varies among lung cancer subtypes.
    Inamura K; Yokouchi Y; Kobayashi M; Ninomiya H; Sakakibara R; Subat S; Nagano H; Nomura K; Okumura S; Shibutani T; Ishikawa Y
    Oncotarget; 2017 Apr; 8(17):28725-28735. PubMed ID: 28404926
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PD-L1 expression and tumor mutational burden status for prediction of response to chemotherapy and targeted therapy in non-small cell lung cancer.
    Chen Y; Liu Q; Chen Z; Wang Y; Yang W; Hu Y; Han W; Zeng H; Ma H; Dai J; Zhang H
    J Exp Clin Cancer Res; 2019 May; 38(1):193. PubMed ID: 31088500
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis.
    Nicholson AG; Gonzalez D; Shah P; Pynegar MJ; Deshmukh M; Rice A; Popat S
    J Thorac Oncol; 2010 Apr; 5(4):436-41. PubMed ID: 20068475
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Distinct patterns of genetic alterations in adenocarcinoma and squamous cell carcinoma of the lung.
    Sy SM; Wong N; Lee TW; Tse G; Mok TS; Fan B; Pang E; Johnson PJ; Yim A
    Eur J Cancer; 2004 May; 40(7):1082-94. PubMed ID: 15093586
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genome analyses identify the genetic modification of lung cancer subtypes.
    Zhang Y; Wang DC; Shi L; Zhu B; Min Z; Jin J
    Semin Cancer Biol; 2017 Feb; 42():20-30. PubMed ID: 27845189
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular cytogenetic analysis of non-small cell lung carcinoma by spectral karyotyping and comparative genomic hybridization.
    Luk C; Tsao MS; Bayani J; Shepherd F; Squire JA
    Cancer Genet Cytogenet; 2001 Mar; 125(2):87-99. PubMed ID: 11369051
    [TBL] [Abstract][Full Text] [Related]  

  • 40. EGFR and KRAS Mutations in ALK-Positive Lung Adenocarcinomas: Biological and Clinical Effect.
    Sahnane N; Frattini M; Bernasconi B; Zappa F; Schiavone G; Wannesson L; Antonelli P; Balzarini P; Sessa F; Mazzucchelli L; Tibiletti MG; Martin V
    Clin Lung Cancer; 2016 Jan; 17(1):56-61. PubMed ID: 26381283
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 58.